Highest-materiality recent filing
Beta Bionics prices $150M public offering of common stock and pre-funded warrants
Priced 7,652,175 common shares at $17.25 and 1,043,484 pre-funded warrants at $17.2499 per share.
FDA clears Beta Bionics Mint patch pump; 3D Intelligence 510(k) submitted
Mint FDA clearance announced Sept 14, 2026; full U.S. launch expected Q1 2027, ahead of prior target; at least 1.5M disposable units capacity in 2027.
Beta Bionics Q2 net sales up 38% to $32M; gross margin expands 524 bps to 59%
Net sales $32.0M, up 38% YoY; PBP channel sales surged 153% to $11.6M.
Beta Bionics reports 2026 Annual Meeting voting results; directors elected, auditor ratified
Class I directors Sean D. Carney and Christy Jones elected with 30.7M and 25.9M votes for, respectively.
Beta Bionics targets Q2 2027 commercialization for Mint patch pump
Expects full commercialization of Mint patch pump by end of Q2 2027, subject to FDA clearance.
Beta Bionics Q1 net sales up 57% YoY to $27.6M; raises FY 2026 guidance
Net sales $27.6M (+57% YoY); PBP channel $10.7M (+181% YoY).
Beta Bionics Q4 2025 revenue $32.1M (+57% YoY); guides FY2026 $130-135M
Net sales $32.1M in Q4 (+57% YoY); full year $100.3M (+54%). Installed base 35,011 users (+129%).
FDA Warning Letter follows June 2025 inspection of Irvine facility; cites non-conformities in Quality Management System, Medical Device Reporting, and Corrections/Removals.
Beta Bionics preliminary Q4 2025 net sales ≥$32M, up >56% YoY; installed base >35K
Net sales expected ≥$32.0M, up >56% from $20.4M in Q4 2024.
Beta Bionics Q3 sales up 63% YoY to $27.3M; raises full-year 2025 guidance
Net sales $27.3M (+63% YoY); DME $21.0M (+45%), PBP $6.2M (+178%).
Beta Bionics Q2 net sales up 54% to $23.2M; raises full-year guidance
Net sales $23.2M (+54% YoY); DME channel $18.6M (+31%), PBP channel $4.6M (+498%).
Beta Bionics reports real-world iLet data: HbA1c drops from 8.9% to 7.3% in 14,952 users
16,439 iLet users uploaded data in first 2 years; 14,952 with baseline HbA1c showed avg drop from 8.9% to 7.3% GMI.
Beta Bionics Q1 revenue up 36% to $17.6M; net loss widens; raises 2025 guidance
Net sales $17.6M (+36% YoY); DME $13.8M (+14%), PBP $3.8M (+360%).
Beta Bionics appoints Gerard Michel as Class III director
Gerard Michel appointed to board effective March 26, 2025; term expires at 2028 annual meeting.
Beta Bionics Q4 revenue up 145% to $20.4M; FY2025 guidance $80-85M
Q4 net sales $20.4M (+145% YoY); FY2024 net sales $65.1M (+443% YoY). Installed base 15,298 users (+564%).
Beta Bionics closes upsized IPO of 13.8M shares at $17.00, raises $229.1M
IPO of 13,800,000 shares at $17.00/share, including full exercise of underwriters' option for 1,800,000 additional shares.
On March 26, 2025, the Board of Directors (the “Board”) of Beta Bionics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Gerard Michel as a Class III director of the Company, with a term of office expiring at the 2028 annual meeting of stockholders.
Max materiality 0.85 · Median 0.72 · Most common event earnings